Join Growin Stock Community!

Xtl biopharmaceuticals ltd.XTLB.US Overview

US StockHealthcare
(No presentation for XTLB)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

XTLB AI Insights

XTLB Overall Performance

XTLB AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

XTLB Recent Performance

-10.64%

Xtl biopharmaceuticals ltd.

0.05%

Avg of Sector

-0.31%

S&P500

XTLB PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

XTLB Key Information

XTLB Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

XTLB Profile

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.

Price of XTLB

XTLB FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

XTLB Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.75
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
7.46
PB Ratio
0.97
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
26.39%
Net Margin
-227.72%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
595100.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.75
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
7.46
PB Ratio
0.97
Price-to-FCF
-
Gross Margin
26.39%
Net Margin
-227.72%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
595100.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is XTLB's latest earnings report released?

    The most recent financial report for Xtl biopharmaceuticals ltd. (XTLB) covers the period of 2024Q4 and was published on 2024/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating XTLB's short-term business performance and financial health. For the latest updates on XTLB's earnings releases, visit this page regularly.

  • What is the operating profit of XTLB?

    According to the latest financial report, Xtl biopharmaceuticals ltd. (XTLB) reported an Operating Profit of -812K with an Operating Margin of -280.97% this period, representing a decline of 306% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How much cash does XTLB have?

    At the end of the period, Xtl biopharmaceuticals ltd. (XTLB) held Total Cash and Cash Equivalents of 371K, accounting for 0.04 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does XTLB go with three margins increasing?

    In the latest report, Xtl biopharmaceuticals ltd. (XTLB) did not achieve the “three margins increasing” benchmark, with a gross margin of 100%%, operating margin of -471.6%%, and net margin of -341.36%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess XTLB's profit trajectory and future growth potential.

  • Is XTLB's EPS continuing to grow?

    According to the past four quarterly reports, Xtl biopharmaceuticals ltd. (XTLB)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.16. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What are the PEG ratio and PE ratio of XTLB?

    The latest valuation data shows Xtl biopharmaceuticals ltd. (XTLB) has a Price-To-Earnings (PE) ratio of -5.91 and a Price/Earnings-To-Growth (PEG) ratio of 0.26. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.